| Host: |
HEK293 cells |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human B7-H1/PD-L1/CD274-C-His & Avi protein was developed from hek293 cells and has a target region of C-His & Avi. For use in research applications. |
| Conjugation: |
Biotin |
| Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Immunoreactivity: |
Immobilized Biotinylated Human PD-L1 at 0.5 Mu g/mL (100 Mu L/Well). Dose response curve for Anti-PD-L1 Ab with the EC50 of 11.3 ng/mL determined by ELISA. |
| Gene Symbol: |
CD274 |
| Gene ID: |
29126 |
| Uniprot ID: |
PD1L1_HUMAN |
| Immunogen Region: |
Phe19-Arg238 |
| Immunogen: |
Biotinylated Recombinant Human PD-L1 Protein is produced by Expi293 expression system. The target protein is expressed with sequence (Phe19-Arg238) of Human PD-L1 fused with His tag and Avi tag at the C-terminal. |
| Post Translational Modifications | Ubiquitinated.STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. Ubiquitinated by MARCHF8.leading to degradation. |
| Function | Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. |
| Protein Name | Programmed Cell Death 1 Ligand 1Pd-L1Pdcd1 Ligand 1Programmed Death Ligand 1Hpd-L1B7 Homolog 1B7-H1Cd Antigen Cd274 |
| Database Links | Reactome: R-HSA-389948Reactome: R-HSA-9701898 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinEarly Endosome MembraneRecycling Endosome MembraneNucleusAssociates With Cmtm6 At Recycling EndosomesWhere It Is Protected From Being Targeted For Lysosomal DegradationTranslocates To The Nucleus In Response To Hypoxia Via Its Interaction With Phosphorylated Stat3Isoform 1: Cell MembraneIsoform 2: Endomembrane SystemIsoform 4: Secreted |
| Alternative Protein Names | Programmed Cell Death 1 Ligand 1 proteinPd-L1 proteinPdcd1 Ligand 1 proteinProgrammed Death Ligand 1 proteinHpd-L1 proteinB7 Homolog 1 proteinB7-H1 proteinCd Antigen Cd274 proteinCD274 proteinB7H1 proteinPDCD1L1 proteinPDCD1LG1 proteinPDL1 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
